Greenwich LifeSciences CEO Snehal Patel buys $23,940 in inventory

In a current SEC submitting, Greenwich LifeSciences, Inc. (NASDAQ:GLSI) disclosed that its CEO and CFO, Snehal Patel, has acquired 2,000 shares of the corporate’s frequent inventory. This transaction, which occurred on January 2, 2025, was executed at a value of $11.97 per share, totaling roughly $23,940. The inventory has since proven sturdy momentum, gaining over 18% previously week to commerce at $12.88. InvestingPro evaluation signifies excessive inventory value volatility, with shares buying and selling between $8 and $21.44 over the previous 52 weeks. Following this buy, Patel holds a complete of 5,543,702 shares instantly, representing a good portion of the corporate’s $169.3 million market capitalization. This transfer displays Patel’s continued funding within the pharmaceutical firm, which makes a speciality of growing modern therapies. InvestingPro information reveals the corporate maintains sturdy liquidity with a present ratio of 6.91, although subscribers can entry 7 further key insights about GLSI’s monetary well being and market place.

In different current information, Greenwich LifeSciences reported noteworthy outcomes from its Annual Assembly of Stockholders. Key developments embody the re-election of all 5 director nominees, David McWilliams, Snehal S. Patel, Eric Rothe, F. Joseph Daugherty, M.D., and Kenneth Hallock, with every receiving over 7.8 million votes. The corporate’s impartial registered public accounting agency, RBSM, LLP, was additionally ratified for the fiscal yr ending December 31, 2024.

An necessary modification to the corporate’s 2019 Fairness Incentive Plan was authorized, elevating the variety of shares reserved for issuance beneath the plan from 1,500,000 to 4,000,000. This proposal obtained over 8 million votes in favor, demonstrating sturdy shareholder assist. Based on InvestingPro, the corporate maintains a powerful liquidity place, indicated by a present ratio of 6.91.

Regardless of not presently being worthwhile, Greenwich LifeSciences has been given a promising value goal of $38 by analysts, suggesting a possible upside. These current developments underscore the shareholders’ confidence within the firm’s present management and strategic initiatives.

This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.